Precigen CFO Buys 8284 Shares at $3.62/Share and 2932 Shares at $3.42/Share.

Precigen, Inc. [PGEN] reports that Chief Financial Officer Thomasian Harry Jr. has made two recent transactions. On September 25, 2025, he acquired 8,284 shares at a price of $3.62 per share. One day later, on September 26, 2025, he purchased 2,932 shares at a price of $3.42 per share.

Precigen, Inc. [PGEN], a biopharmaceutical company focused on gene and cell therapies, has seen its shares rally following the FDA approval of its therapy Papzimeos for recurrent respiratory papillomatosis (RRP). The company's Chief Financial Officer, Thomasian Harry Jr., has recently made two significant share purchases, indicating his confidence in the company's prospects.

On September 25, 2025, CFO Harry Jr. acquired 8,284 shares at a price of $3.62 per share. The following day, on September 26, 2025, he purchased an additional 2,932 shares at a price of $3.42 per share. These transactions total $31,742.88 in value.

The purchases come after the company secured a $125 million credit facility agreement with Pharmakon Advisors, providing the company with a substantial cash infusion to support the commercialization of Papzimeos. The FDA approval of Papzimeos, which demonstrated a 51% complete response rate and an 86% reduction in the need for surgeries, has positioned Precigen as a leader in the RRP treatment market.

While the company faces competition from Inovio Pharmaceuticals' INO-3107, which also targets HPV6 and HPV11, Precigen's first-mover advantage and superior safety profile could provide a significant edge. The market opportunity for Papzimeos is substantial, with a total addressable domestic market of approximately $12.4 billion.

The recent share purchases by CFO Harry Jr. suggest that the company's management is bullish on its prospects. However, investors should remain cautious given the company's history of shareholder value destruction and the uncertainty surrounding its profitability.